Skin-device test to find drugs for T-cell lymphoma lesions
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a tiny device placed directly into skin lymphoma spots to help identify which “candidate” drugs could work. It’s mainly aimed at people with measurable skin involvement from T-cell lymphoma, after they stop certain treatments for a set time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have biopsy-proven cutaneous (skin) T-cell lymphoma, with measurable skin lesions
- At least two skin lesions are large enough and in suitable spots (about 1.5 cm or more) for device placement
- You’re 18 or older, and your general health is good enough for procedures (ECOG 0–2)
- You can wait through treatment washout times (no certain skin and body-wide treatments for set periods before and around device use)
- Your blood counts are adequate (neutrophils and platelets meet minimum levels within 28 days of the procedure)
- You’re able and willing to manage the device at home and sign consent, including genetic/genomic testing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing new treatment plans based on the genetic type of your cutaneous T-cell lymphoma (CTCL). It's for people whose CTCL did not respond well to standard skin treatments.
This trial tests a treatment called photopheresis to treat early-stage mycosis fungoides, a type of skin lymphoma. It may help reduce or control skin patches or plaques that have not responded well to standard treatments.
This trial looks at the results of different systemic (whole-body) treatments for cutaneous T-cell lymphoma (CTCL), a rare type of lymphoma that affects the skin. It aims to understand how well these therapies work and help guide future treatment choices.
This study looks at the bacteria (microbiome) living on the skin in people with specific skin conditions, and in healthy volunteers. The results may help researchers understand what skin microbes have to do with these diseases.
This trial is testing a cream called tofacitinib (a type of medicine that helps calm the immune system) for people with early-stage cutaneous T-cell lymphoma (CTCL). The goal is to see if it helps shrink or control the skin lesions safely.
This trial tests a gel form of a drug called duvelisib that you apply directly to skin lesions. It is for people with early-stage mycosis fungoides and may help control the patches without needing whole-body treatments.
Hear when a new Cutaneous T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.